source
- FDA clears Protagonist-Takeda therapy for rare blood cancer as Lilly moves to buy Merida for up to $2.88 billionThe U.S. Food and Drug Administration has granted approval to a collaborative therapy from Protagonist and Takeda aimed at treating a rare form of blood cancer. This regulatory decision adds a new…
- Sanofi-backed Electra Therapeutics files for Nasdaq IPO to fund Phase 2/3 immunology programElectra Therapeutics announced it has filed with securities regulators to begin trading on the Nasdaq shortly after the Labor Day holiday. The Sanofi-backed biotech aims to raise capital through t…Endpoints · 2mo agoDealPositive